| H3Africa: current perspectives |
21 |
| Emerging biomarkers in the diagnosis of prostate cancer |
14 |
| CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment |
13 |
| CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment |
12 |
| Precision pharmacotherapy: psychiatry's future direction in preventing, diagnosing, and treating mental disorders |
10 |
| Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications |
10 |
| Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation |
10 |
| CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort |
9 |
| The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty |
8 |
| Personalized medicine in breast cancer: pharmacogenomics approaches |
8 |
| The utility of pharmacogenetic testing to support the treatment of bipolar disorder |
8 |
| Effects of MTHFR and ABCC2 gene polymorphisms on antiepileptic drug responsiveness in Jordanian epileptic patients |
7 |
| Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients |
5 |
| Personalized treatment options for thyroid cancer: current perspectives |
5 |
| Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy |
5 |
| The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders |
5 |
| Influence of CYP2D CYP3A ABCB APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer's disease and vascular dementia |
5 |
| Pharmacogenomics And Hypertension: Current Insights |
4 |
| Diversity In Precision Medicine And Pharmacogenetics: Methodological And Conceptual Considerations For Broadening Participation |
4 |
| Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke |
4 |
| Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder |
4 |
| Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease |
4 |
| Update on the pharmacogenomics of pain management |
4 |
| VKORCI variants as significant predictors of warfarin dose in Emiratis |
3 |
| Knowledge And Attitudes Of Pharmacy Students Towards Pharmacogenomics Among Universities In Jordan And West Bank Of Palestine |
3 |
| Genetic polymorphisms of CYP3A CHRM and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case-control study |
2 |
| The AKR1D1*36 (rs1872930) Allelic Variant Is Independently Associated With Clopidogrel Treatment Outcome |
2 |
| Identification of genetic variants associated with skeletal muscle function deficit in childhood acute lymphoblastic leukemia survivors |
2 |
| CYP3A and CYP2C19 activity in urine in relation to CYP3A CYP3A and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole |
2 |
| Association between polymorphisms of LEP, LEPR, DRD HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia |
2 |
| Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach |
2 |
| Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov-Smirnov Algorithm |
2 |
| Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges |
2 |
| ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients |
2 |
| OPRM1 A118G Polymorphisms and Its Role in Opioid Addiction: Implication on Severity and Treatment Approaches |
2 |
| The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction |
2 |
| Plasma brain-derived neurotrophic factor (BDNF) concentration and the BDNF Val66Met polymorphism in suicide: a prospective study in patients with depressive disorder |
2 |
| Population's perspectives toward biobanks in scientific research: a study from Jordan |
2 |
| The influence of an IL-4 variable number tandem repeat (VNTR) polymorphism on breast cancer susceptibility |
2 |
| Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population |
1 |
| Qualitative user evaluation of a revised pharmacogenetic educational toolkit |
1 |
| Precision medicine approaches for the management of Ewing sarcoma: current perspectives |
1 |
| Genetic polymorphism of the methotrexate transporter ABCG blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study |
1 |
| A personalized approach to acute myeloid leukemia therapy: current options |
1 |
| Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I-II hypertension |
1 |
| Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery |
1 |
| Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare |
1 |
| Which attributes of whole genome sequencing tests are most important to the general population? Results from a German preference study |
1 |
| Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy |
0 |
| A Novel Mutation Of The EMD Gene In A Family With Cardiac Conduction Abnormalities And A High Incidence Of Sudden Cardiac Death |
0 |
